Drug Profile
Research programme: targeted immunotherapies - Biohaven Labs
Alternative Names: Antibody recruiting molecules - Biohaven Labs; ARMs - Biohaven Labs; SyAMS - Biohaven Labs; Synthetic antibody recruiting molecules - Biohaven LabsLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Yale University
- Developer Kleo Pharmaceuticals
- Class Immunoconjugates; Immunotherapies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 08 Jan 2024 Biohaven expects a total of four IND approvals in 2024
- 07 Jan 2021 Kleo Pharmaceuticals was acquired and merged into Biohaven Pharmaceutical Holding Company to form Biohaven Labs
- 07 Jan 2021 Biohaven Pharmaceutical in-licenses Molecular Degrader of Extracellular Protein (MoDEs) platform technology from Yale University